Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS628 vs Actemra in Moderate to Severe Rheumatoid Arthritis
NCT06048224Phase 3Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HS628 in rheumatoid arthritis (RA) (2 arms), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd. Primary endpoint: American College of Rheumatology 20% Response at Week 24. Started Dec 2020; status: completed.
02
Drugs
HS628
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06048224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048224.